Sonoma Pharmaceuticals, Inc.
SNOA · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.01 | 0.06 | 0.22 |
| FCF Yield | -6.18% | -86.82% | -96.87% | -20.61% |
| EV / EBITDA | 0.66 | -0.06 | -0.82 | -2.67 |
| Quality | ||||
| ROIC | -44.68% | -39.14% | -34.40% | -39.24% |
| Gross Margin | 38.25% | 37.26% | 33.73% | 31.62% |
| Cash Conversion Ratio | 0.03 | 0.50 | 1.19 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.49% | 0.28% | -10.69% | -11.03% |
| Free Cash Flow Growth | 93.04% | 62.39% | -46.43% | -23.28% |
| Safety | ||||
| Net Debt / EBITDA | 1.42 | 0.56 | 0.67 | 1.06 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -588.70 |
| Efficiency | ||||
| Inventory Turnover | 3.03 | 2.94 | 3.08 | 3.24 |
| Cash Conversion Cycle | 177.30 | 268.28 | 154.44 | 112.77 |